Related Experiment Videos
Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease
1Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA.
Insights
Cardiovascular disease (CVD) is a major cause of death in chronic kidney disease (CKD) patients. Studying CVD during the CKD to end-stage renal disease (ESRD) transition can improve patient outcomes.
Area of Science:
- Nephrology
- Cardiology
- Public Health
Background:
- Cardiovascular disease (CVD) is the primary cause of death in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
- High mortality rates persist in patients initiating dialysis.
- The transition period from CKD to ESRD is critical for CVD evolution.
Purpose of the Study:
- To review the epidemiology of subclinical and clinical CVD during the CKD to ESRD transition.
- To discuss clinical trials for CVD therapies in CKD and ESRD patients.
Main Methods:
- Literature review of epidemiological data.
- Analysis of clinical trial outcomes for CVD therapies.
Main Results:
- CVD is highly prevalent and a leading cause of mortality in CKD and ESRD.
- Understanding the natural history of CVD in this population is crucial for timely interventions.
- Ongoing research focuses on therapeutic strategies to mitigate CVD risk.
Conclusions:
- Further research into CVD progression during the CKD-ESRD transition is essential.
- Optimizing CVD therapies during this period may improve survival rates for kidney disease patients.
- This review highlights the need for integrated care strategies for CVD and kidney disease.
Abstract:
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). The rate of death in incident dialysis patients remains high. This has led to interest in the study of the evolution of CVD during the critical transition period from CKD to ESRD. Understanding the natural history and risk factors of clinical and subclinical CVD during this transition may help guide the timing of appropriate CVD therapies to improve outcomes in patients with kidney disease. This review provides an overview of the epidemiology of subclinical and clinical CVD during the transition from CKD to ESRD and discusses clinical trials of CVD therapies to mitigate risk of CVD in CKD and ESRD patients.